Reply from the National Medical Insurance Administration: Accelerate the advancement of traditional Chinese medicine and formula particles into centralized procurement

On August 9, the National Medical Insurance Administration issued a reply to the recommendation No.

The original text is as follows:

National Medical Security Administration on the Fourth Session of the 13th National People's Congress

Reply to Recommendation No.

Medical Insurance Letter (2021) No.

Representative Lu Qingguo:

Your suggestion on accelerating the entry of Chinese medicines and formula granules into centralized procurement has been received.

1.

In accordance with the decisions and deployments of the Party Central Committee and the State Council, starting from 2018, the National Medical Insurance Bureau, in conjunction with relevant departments, has promoted the reform of the centralized drug procurement system in an orderly manner, and successfully carried out five batches of 218 drug centralized procurement

Your suggestion that proprietary Chinese medicines enter the centralized drug procurement as soon as possible, so that more traditional Chinese medicine manufacturers can participate in the competition fairly, we have policy arrangements and preliminary explorations

Second, the next step to consider

We attach great importance to your suggestion of improving the standard system and accelerating the inclusion of proprietary Chinese medicines and formula granules into centralized procurement